Hepatic remnant lipoprotein clearance by heparan sulfate proteoglycans and low-density lipoprotein receptors depend on dietary conditions in mice

Arteriosclerosis, Thrombosis, and Vascular Biology

Volumn 33, Issue 9, 2013, Pages 2065-2074

  Foley, Erin M ^a,b   Gordts, Philip L S M ^a   Stanford, Kristin I ^c   Gonzales, Jon C ^a,b   Lawrence, Roger ^a   Stoddard, Nicole ^a,b   Esko, Jeffrey D ^a,b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c HARVARD UNIVERSITY   (United States)

Author keywords

cholesterol; heparan sulfate proteoglycans; lipoproteins; low density lipoprotein receptor; low density lipoprotein receptor related protein 1; syndecan 1; triglycerides

Indexed keywords

LIPOPROTEIN; LOW DENSITY LIPOPROTEIN RECEPTOR; PROTEOHEPARAN SULFATE; TRIACYLGLYCEROL;

ANIMAL EXPERIMENT; ARTICLE; CHOLESTEROL BLOOD LEVEL; CHOLESTEROL METABOLISM; CONTROLLED STUDY; DIETARY INTAKE; GENE EXPRESSION; GENE INACTIVATION; HYPERLIPIDEMIA; LIPID DIET; LIVER CLEARANCE; MOUSE; MOUSE MUTANT; NONHUMAN; POSTPRANDIAL STATE; PRIORITY JOURNAL;

CHOLESTEROL; HEPARAN SULFATE PROTEOGLYCANS; LIPOPROTEINS; LOW-DENSITY LIPOPROTEIN RECEPTOR; LOW-DENSITY LIPOPROTEIN RECEPTOR-RELATED PROTEIN-1; SYNDECAN-1; TRIGLYCERIDES;

ANIMALS; CELLS, CULTURED; CHOLESTEROL, DIETARY; CHYLOMICRON REMNANTS; DIET, HIGH-FAT; DIETARY SUCROSE; HEPARAN SULFATE PROTEOGLYCANS; HEPATOCYTES; HYPERLIPIDEMIAS; LIVER; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; PARTICLE SIZE; POSTPRANDIAL PERIOD; RECEPTORS, LDL; SULFOTRANSFERASES; TIME FACTORS; TRIGLYCERIDES; TUMOR SUPPRESSOR PROTEINS;

EID: 84883266764     PISSN: 10795642     EISSN: 15244636     Source Type: Journal    
DOI: 10.1161/ATVBAHA.113.301637     Document Type: Article

References (40)

1. Nordestgaard BG, Benn M, Schnohr P, Tybjaerg-Hansen A. Nonfasting triglycerides and risk of myocardial infarction, ischemic heart disease, and death in men and women. JAMA. 2007;298:299-308. (Pubitemid 47080484)
2. Bansal S, Buring JE, Rifai N, Mora S, Sacks FM, Ridker PM. Fasting compared with nonfasting triglycerides and risk of cardiovascular events in women. JAMA. 2007;298:309-316. (Pubitemid 47080485)
3. Yuan G, Al-Shali KZ, Hegele RA. Hypertriglyceridemia: its etiology, effects and treatment. CMAJ. 2007;176:1113-1120. (Pubitemid 46649735)
4. Stalenhoef AF, de Graaf J. Association of fasting and nonfasting serum triglycerides with cardiovascular disease and the role of remnant-like lipoproteins and small dense LDL. Curr Opin Lipidol. 2008;19:355-361.
5. Foley EM, Esko JD. Hepatic heparan sulfate proteoglycans and endocytic clearance of triglyceride-rich lipoproteins. Prog Mol Biol Transl Sci. 2010;93:213-233.
6. Mahley RW, Huang Y. Atherogenic remnant lipoproteins: role for proteoglycans in trapping, transferring, and internalizing. J Clin Invest. 2007;117:94-98. (Pubitemid 46048456)
7. Williams KJ, Chen K. Recent insights into factors affecting remnant lipoprotein uptake. Curr Opin Lipidol. 2010;21:218-228.
8. Ishibashi S, Perrey S, Chen Z, Osuga Ji, Shimada M, Ohashi K, Harada K, Yazaki Y, Yamada N. Role of the low density lipoprotein (LDL) receptor pathway in the metabolism of chylomicron remnants. A quantitative study in knockout mice lacking the LDL receptor, apolipoprotein E, or both. J Biol Chem. 1996;271:22422-22427. (Pubitemid 26304676)
9. Rohlmann A, Gotthardt M, Hammer RE, Herz J. Inducible inactivation of hepatic LRP gene by cre-mediated recombination confirms role of LRP in clearance of chylomicron remnants. J Clin Invest. 1998;101:689-695. (Pubitemid 28084254)
10. Fujino T, Asaba H, Kang MJ, et al. Low-density lipoprotein receptor-related protein 5 (LRP5) is essential for normal cholesterol metabolism and glucoseinduced insulin secretion. Proc Natl Acad Sci USA. 2003;100:229-234. (Pubitemid 36078057)
11. Stanford KI, Bishop JR, Foley EM, Gonzales JC, Niesman IR, Witztum JL, Esko JD. Syndecan-1 is the primary heparan sulfate proteoglycan mediating hepatic clearance of triglyceride-rich lipoproteins in mice. J Clin Invest. 2009;119:3236-3245.
12. Goudriaan JR, Espirito Santo SM, Voshol PJ, Teusink B, van Dijk KW, van Vlijmen BJ, Romijn JA, Havekes LM, Rensen PC. The VLDL receptor plays a major role in chylomicron metabolism by enhancing LPLmediated triglyceride hydrolysis. J Lipid Res. 2004;45:1475-1481. (Pubitemid 39006975)
13. Van Eck M, Hoekstra M, Out R, Bos IS, Kruijt JK, Hildebrand RB, Van Berkel TJ. Scavenger receptor BI facilitates the metabolism of VLDL lipoproteins in vivo. J Lipid Res. 2008;49:136-146.
14. Mann CJ, Khallou J, Chevreuil O, Troussard AA, Guermani LM, Launay K, Delplanque B, Yen FT, Bihain BE. Mechanism of activation and functional significance of the lipolysis-stimulated receptor. Evidence for a role as chylomicron remnant receptor. Biochemistry. 1995;34:10421-10431.
15. MacArthur JM, Bishop JR, Stanford KI, Wang L, Bensadoun A, Witztum JL, Esko JD. Liver heparan sulfate proteoglycans mediate clearance of triglyceride-rich lipoproteins independently of LDL receptor family members. J Clin Invest. 2007;117:153-164. (Pubitemid 46048462)
16. Lawrence R, Olson SK, Steele RE, Wang L, Warrior R, Cummings RD, Esko JD. Evolutionary differences in glycosaminoglycan fine structure detected by quantitative glycan reductive isotope labeling. J Biol Chem. 2008;283:33674-33684.
17. Lawrence R, Lu H, Rosenberg RD, Esko JD, Zhang L. Disaccharide structure code for the easy representation of constituent oligosaccharides from glycosaminoglycans. Nat Methods. 2008;5:291-292. (Pubitemid 351455150)
18. Espirito Santo SM, Pires NM, Boesten LS, Gerritsen G, Bovenschen N, van Dijk KW, Jukema JW, Princen HM, Bensadoun A, Li WP, Herz J, Havekes LM, van Vlijmen BJ. Hepatic low-density lipoprotein receptorrelated protein deficiency in mice increases atherosclerosis independent of plasma cholesterol. Blood. 2004;103:3777-3782. (Pubitemid 38596295)
19. Gonzales JC, Gordts PL, Foley EM, Esko JD. Apolipoproteins E and AV mediate lipoprotein clearance by hepatic proteoglycans. J Clin Invest. 2013;123:2742-2751.
20. Williams KJ, Fless GM, Petrie KA, Snyder ML, Brocia RW, Swenson TL. Mechanisms by which lipoprotein lipase alters cellular metabolism of lipoprotein(a), low density lipoprotein, and nascent lipoproteins. Roles for low density lipoprotein receptors and heparan sulfate proteoglycans. J Biol Chem. 1992;267:13284-13292.
21. Ji ZS, Brecht WJ, Miranda RD, Hussain MM, Innerarity TL, Mahley RW. Role of heparan sulfate proteoglycans in the binding and uptake of apolipoprotein E-enriched remnant lipoproteins by cultured cells. J Biol Chem. 1993;268:10160-10167. (Pubitemid 23150196)
22. Ji ZS, Dichek HL, Miranda RD, Mahley RW. Heparan sulfate proteoglycans participate in hepatic lipase and apolipoprotein E-mediated binding and uptake of plasma lipoproteins, including high density lipoproteins. J Biol Chem. 1997;272:31285-31292. (Pubitemid 28013260)
23. Ji ZS, Sanan DA, Mahley RW. Intravenous heparinase inhibits remnant lipoprotein clearance from the plasma and uptake by the liver: in vivo role of heparan sulfate proteoglycans. J Lipid Res. 1995;36:583-592.
24. Mortimer BC, Beveridge DJ, Martins IJ, Redgrave TG. Intracellular localization and metabolism of chylomicron remnants in the livers of low density lipoprotein receptor-deficient mice and apoE-deficient mice. Evidence for slow metabolism via an alternative apoE-dependent pathway. J Biol Chem. 1995;270:28767-28776.
25. Windler E, Greeve J, Robenek H, Rinninger F, Greten H, Jäckle S. Differences in the mechanisms of uptake and endocytosis of small and large chylomicron remnants by rat liver. Hepatology. 1996;24:344-351. (Pubitemid 26260030)
26. Mann WA, Lohse P, Gregg RE, Ronan R, Hoeg JM, Zech LA, Brewer HB Jr. Dominant expression of type III hyperlipoproteinemia. Pathophysiological insights derived from the structural and kinetic characteristics of ApoE-1 (Lys146-Glu). J Clin Invest. 1995;96:1100-1107.
27. Mann WA, Meyer N, Weber W, Meyer S, Greten H, Beisiegel U. Apolipoprotein E isoforms and rare mutations: parallel reduction in binding to cells and to heparin reflects severity of associated type III hyperlipoproteinemia. J Lipid Res. 1995;36:517-525.
28. Stanford KI, Wang L, Castagnola J, Song D, Bishop JR, Brown JR, Lawrence R, Bai X, Habuchi H, Tanaka M, Cardoso WV, Kimata K, Esko JD. Heparan sulfate 2-O-sulfotransferase is required for triglyceride-rich lipoprotein clearance. J Biol Chem. 2010;285:286-294.
29. Deng Y, Foley EM, Gonzales JC, Gordts PL, Li Y, Esko JD. Shedding of syndecan-1 from human hepatocytes alters very low density lipoprotein clearance. Hepatology. 2012;55:277-286.
30. Kita T, Goldstein JL, Brown MS, Watanabe Y, Hornick CA, Havel RJ. Hepatic uptake of chylomicron remnants in WHHL rabbits: a mechanism genetically distinct from the low density lipoprotein receptor. Proc Natl Acad Sci USA. 1982;79:3623-3627. (Pubitemid 12014522)
31. Rubinsztein DC, Cohen JC, Berger GM, van der Westhuyzen DR, Coetzee GA, Gevers W. Chylomicron remnant clearance from the plasma is normal in familial hypercholesterolemic homozygotes with defined receptor defects. J Clin Invest. 1990;86:1306-1312. (Pubitemid 20370439)
32. May P, Woldt E, Matz RL, Boucher P. The LDL receptor-related protein (LRP) family: an old family of proteins with new physiological functions. Ann Med. 2007;39:219-228. (Pubitemid 46676481)
33. de Faria E, Fong LG, Komaromy M, Cooper AD. Relative roles of the LDL receptor, the LDL receptor-like protein, and hepatic lipase in chylomicron remnant removal by the liver. J Lipid Res. 1996;37:197-209. (Pubitemid 26052631)
34. Espirito Santo SM, Rensen PC, Goudriaan JR, Bensadoun A, Bovenschen N, Voshol PJ, Havekes LM, van Vlijmen BJ. Triglyceride-rich lipoprotein metabolism in unique VLDL receptor, LDL receptor, and LRP triple-deficient mice. J Lipid Res. 2005;46:1097-1102. (Pubitemid 43109825)
35. Yen FT, Roitel O, Bonnard L, Notet V, Pratte D, Stenger C, Magueur E, Bihain BE. Lipolysis stimulated lipoprotein receptor: a novel molecular link between hyperlipidemia, weight gain, and atherosclerosis in mice. J Biol Chem. 2008;283:25650-25659.
36. Rensen PC, Herijgers N, Netscher MH, Meskers SC, van Eck M, van Berkel TJ. Particle size determines the specificity of apolipoprotein E-containing triglyceride-rich emulsions for the LDL receptor versus hepatic remnant receptor in vivo. J Lipid Res. 1997;38:1070-1084. (Pubitemid 27281803)
37. Elson-Schwab L, Garner OB, Schuksz M, Crawford BE, Esko JD, Tor Y. Guanidinylated neomycin delivers large, bioactive cargo into cells through a heparan sulfate-dependent pathway. J Biol Chem. 2007;282:13585-13591. (Pubitemid 47100528)
38. Belting M. Heparan sulfate proteoglycan as a plasma membrane carrier. Trends Biochem Sci. 2003;28:145-151. (Pubitemid 36293852)
39. Williams KJ, Fuki IV. Cell-surface heparan sulfate proteoglycans: dynamic molecules mediating ligand catabolism. Curr Opin Lipidol. 1997;8:253-262. (Pubitemid 27462431)
40. Wilsie LC, Orlando RA. The low density lipoprotein receptor-related protein complexes with cell surface heparan sulfate proteoglycans to regulate proteoglycan-mediated lipoprotein catabolism. J Biol Chem. 2003;278:15758-15764. (Pubitemid 36799688)